BTTX

Better Therapeutics, Inc. [BTTX] Stock Forecast

Q: What is Better Therapeutics, Inc. stock symbol ?

Better Therapeutics, Inc. is a US stock, located in San francisco of Ca and trading under the symbol BTTX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

BTTX Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

Currently unprofitable, and not expected to turn profitable in the coming year

Does not have any significance market cap ($10.98M)

BTTX has less than 1 year of cash runway

Top BTTX Correlated Resources

BTTX

Top 10 Correlated ETFs

BTTX

Top 10 Correlated Stocks

BTTX

In the News

10:34 11 Dec 2023 BTTX

Better Therapeutics, Inc. (BTTX) Q2 2023 Earnings Call Transcript

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Keay Nakae - Chardan Rahul Rakhit - LifeSci Capital Operator Good day and thank you for standing by, and welcome to the Better Therapeutics' Second Quarter 2023 Update Call. At this time all participants are in a listen-only mode.

05:30 11 Dec 2023 BTTX

Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the market closes on Wednesday, August 09, 2023. Management will host a conference call and webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 09, 2023. To access the conference call, please register at: https://re.

08:57 11 Dec 2023 BTTX

Why Is Better Therapeutics (BTTX) Stock Up 39% Today?

Better Therapeutics (NASDAQ: BTTX ) stock is taking off on Tuesday as investors react to approval from the FDA for a Type 2 diabetes treatment. This covers AspyreRx, which is a prescription-only digital therapeutic treatment for patients 18 and older with Type 2 diabetes.

04:13 11 Dec 2023 BTTX

Better Therapeutics, Inc. (BTTX) Q1 2023 Earnings Call Transcript

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Mark Heinen - CFO Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Lucas Romanski - TD Cowen Keay Nakae - Chardan Keay Rahul Rakhit - LifeSci Capital Operator Good morning and thank you for standing by, and welcome to the Better Therapeutics' First Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.

01:42 11 Dec 2023 BTTX

Better Therapeutics, Inc. (BTTX) Moves to Buy: Rationale Behind the Upgrade

Better Therapeutics, Inc. (BTTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10:27 11 Dec 2023 BTTX

Better Therapeutics, Inc. (BTTX) Q3 2022 - Earnings Call Transcript

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and Chief Executive Officer Mark Berman - Chief Medical Officer Diane Gómez-Thinnes - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Operator Good afternoon, and welcome to the Better Therapeutics Third Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

06:34 11 Dec 2023 BTTX

Better Therapeutics, Inc. (BTTX) CEO Frank Karbe on Q2 2022 Results - Earnings Call Transcript

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Mark Heinen – Chief Financial Officer Frank Karbe – President and Chief Executive Officer Mark Berman – Chief Medical Officer Conference Call Participants Thomas Flaten – Lake Street Capital Rahul Rakhit – LifeSci Capital Keay Nakae – Chardan Operator Good morning, and welcome to the Better Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

11:10 11 Dec 2023 BTTX

Why Is Better Therapeutics (BTTX) Stock Up 27% Today?

Source: Minerva Studio / Shutterstock.com Better Therapeutics (NASDAQ: BTTX ) stock is rocketing higher on Thursday as investors react to results from a Phase 2 clinical trial. This Phase 2 study saw Better Therapeutics using BT-001 to treat type 2 diabetes.

07:30 11 Dec 2023 BTTX

Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes. Members of the Better Therapeutics managemen

07:45 11 Dec 2023 BTTX

3 Penny Stocks That Have Huge Catalysts Ahead

While you don't want to play with money you can't afford to lose, these penny stocks might bring home the goods for the bold. The post 3 Penny Stocks That Have Huge Catalysts Ahead appeared first on InvestorPlace.

BTTX Financial details

Company Rating

Neutral

Market Cap

10.98M

Income

-31.57M

Revenue

Book val./share

-0.26

Cash/share

0.17

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

09 Nov 2023

P/E

-0.28

Forward P/E

-0.41

PEG

0.04

P/S

P/B

-0.9

P/C

1.36

P/FCF

-0.4

Quick Ratio

0.51

Current Ratio

0.57

Debt / Equity

-1.44

LT Debt / Equity

-0.78

EPS (TTM)

-1.15

EPS next Y

-0.56

EPS next Q

-0.19

EPS this Y

-45.66%

EPS next Y

-51.3%

EPS next 5Y

-6.09%

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-37.5%

SMA20

40%

SMA50

-43.24%

SMA100

-75.86%

Inst Own

6.07%

Inst Trans

1.34%

ROA

-294%

ROE

401%

ROC

13.36%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

47.4M

Shs Float

23.31M

Target Price

52W Range

0.137-1.61

52W High

52W Low

RSI

57.82

Rel Volume

0.24

Avg Volume

Volume

474.42K

Perf Week

21.89%

Perf Month

21.45%

Perf Quarter

-74.96%

Perf Half Y

-69.92%

Beta

2.472

Volatility

0.02%, 0.03%

Prev Close

-1.49%

Price

0.2316

Change

0.52%

BTTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0
Net income per share	-0.25	-0.27	-3.11	-1.69
Operating cash flow per share	-0.26	-0.24	-2.37	-1.23
Free cash flow per share	-0.38	-0.34	-2.46	-1.28
Cash per share	0.03	0.01	3.12	0.67
Book value per share	-0.03	-0.29	2.83	-0.04
Tangible book value per share	-0.16	-0.52	2.44	-0.2
Share holders equity per share	-0.03	-0.29	2.83	-0.04
Interest debt per share	0.21	0.03	0.75	0.69
Market cap	236M	236M	60.37M	26.15M
Enterprise value	240.24M	236.51M	29.31M	25.29M
P/E ratio	-40.72	-36.95	-1.5	-0.66
Price to sales ratio	13.11K	29.5K	0	0
POCF ratio	-37.96	-40.87	-1.96	-0.9
PFCF ratio	-26.36	-29.21	-1.89	-0.87
P/B Ratio	-390.08	-34.92	1.64	-29.09
PTB ratio	-390.08	-34.92	1.64	-29.09
EV to sales	13.35K	29.56K	0	0
Enterprise value over EBITDA	-42.14	-37.85	-0.96	-0.66
EV to operating cash flow	-38.64	-40.96	-0.95	-0.87
EV to free cash flow	-26.83	-29.28	-0.92	-0.84
Earnings yield	-0.02	-0.03	-0.67	-1.52
Free cash flow yield	-0.04	-0.03	-0.53	-1.15
Debt to equity	-8.26	-0.09	0.26	-16.55
Debt to assets	1.02	0.1	0.19	0.65
Net debt to EBITDA	-0.74	-0.08	1.02	0.02
Current ratio	2.03	0.76	9.56	1.37
Interest coverage	-524.82	-63.23	-165.19	-25.66
Income quality	1.07	0.9	0.76	0.73
Dividend Yield	0	0	0	0
Payout ratio	0	0	0	0
Sales general and administrative to revenue	122.06	306.88	0	0
Research and developement to revenue	127.22	372.25	0	0
Intangibles to total assets	0.67	0.87	0.1	0.17
Capex to operating cash flow	0.44	0.4	0.03	0.04
Capex to revenue	-152	-288.13	0	0
Capex to depreciation	-38	-30.73	-0.66	-0.43
Stock based compensation to revenue	4.67	29.13	0	0
Graham number	0.38	1.32	14.06	1.2
ROIC	-1.32	1.06	-0.66	-2.74
Return on tangible assets	-3.59	-7.68	-0.88	-2.09
Graham Net	-0.2	-0.55	2.03	-0.34
Working capital	501K	-150K	40.52M	4.95M
Tangible asset value	-3.87M	-12.31M	31.64M	-4.79M
Net current asset value	-4.5M	-12.68M	31.01M	-5.4M
Invested capital	-8.26	-0.09	0.26	-16.55
Average receivables	0	0	0	0
Average payables	0	424.5K	1.02M	2.28M
Average inventory	0	0	0	0
Days sales outstanding	0	0	0	0
Days payables outstanding	136.16	275.09	0	0
Days of inventory on hand	0	0	0	0
Receivables turnover	0	0	0	0
Payables turnover	2.68	1.33	0	0
Inventory turnover	0	0	0	0
ROE	9.58	0.95	-1.1	44.23
Capex per share	-0.12	-0.1	-0.08	-0.05

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.48	-0.37	-0.39	-0.24	-0.15
Operating cash flow per share	-0.3	-0.27	-0.37	-0.16	-0.15
Free cash flow per share	-0.31	-0.28	-0.39	-0.18	-0.15
Cash per share	0.94	0.66	0.25	0.2	0.17
Book value per share	0.31	-0.04	-0.41	-0.35	-0.26
Tangible book value per share	0.13	-0.2	-0.57	-0.46	-0.33
Share holders equity per share	0.31	-0.04	-0.41	-0.35	-0.26
Interest debt per share	0.64	0.65	0.63	0.47	0.36
Market cap	41.7M	26.36M	16.68M	33.71M	14.09M
Enterprise value	34.18M	25.5M	25.15M	41.73M	21.8M
P/E ratio	-0.91	-0.75	-0.45	-1.11	-0.6
Price to sales ratio	0	0	0	0	0
POCF ratio	-5.94	-4.16	-1.91	-6.63	-2.37
PFCF ratio	-5.65	-3.94	-1.81	-6.03	-2.37
P/B Ratio	5.75	-29.32	-1.7	-3.12	-1.42
PTB ratio	5.75	-29.32	-1.7	-3.12	-1.42
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-3.32	-3.06	-2.82	-6.7	-4.08
EV to operating cash flow	-4.87	-4.02	-2.89	-8.2	-3.67
EV to free cash flow	-4.63	-3.81	-2.72	-7.46	-3.66
Earnings yield	-0.27	-0.33	-0.56	-0.23	-0.42
Free cash flow yield	-0.18	-0.25	-0.55	-0.17	-0.42
Debt to equity	2.04	-16.55	-1.48	-1.32	-1.44
Debt to assets	0.52	0.65	1.14	1.22	1.33
Net debt to EBITDA	0.73	0.1	-0.95	-1.29	-1.44
Current ratio	2.52	1.37	0.62	0.53	0.57
Interest coverage	-27.08	-18.96	-20.71	-12.48	10.31
Income quality	0.62	0.72	0.93	0.67	1.01
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.15	0.17	0.29	0.31	0.26
Capex to operating cash flow	0.05	0.06	0.06	0.1	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.52	-0.5	-0.69	-0.63	-0.01
Stock based compensation to revenue	0	0	0	0	0
Graham number	1.82	0.56	1.91	1.37	0.94
ROIC	-0.5	-0.6	-1.9	-2.05	-1.22
Return on tangible assets	-0.47	-0.46	-1.03	-0.95	-0.74
Graham Net	0.06	-0.34	-0.7	-0.52	-0.37
Working capital	14.18M	4.95M	-5.2M	-6.45M	-5.59M
Tangible asset value	3.13M	-4.79M	-13.59M	-14.37M	-12.73M
Net current asset value	2.52M	-5.4M	-14.2M	-14.97M	-13.31M
Invested capital	2.04	-16.55	-1.48	-1.32	-1.44
Average receivables	0	0	0	0	0
Average payables	1.17M	2.15M	2.77M	2.75M	2.65M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-1.57	9.75	0.95	0.7	0.59
Capex per share	-0.02	-0.02	-0.02	-0.02	0

BTTX Frequently Asked Questions

What is Better Therapeutics, Inc. stock symbol ?

Better Therapeutics, Inc. is a US stock , located in San francisco of Ca and trading under the symbol BTTX

What is Better Therapeutics, Inc. stock quote today ?

Better Therapeutics, Inc. stock price is $0.2316 today.

Is Better Therapeutics, Inc. stock public?

Yes, Better Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 2M
Market Capitalization 10.98M
Employee 54
CEO Mr. Frank L. Karbe
Headquarters San Francisco,CA,US
IPO Date 2021-03-17
Website https://www.bettertx.com

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.